Evidence map›Paper›PMID 27837149›Full record

ArticleJournal of the American Society of Nephrology : JASN2017

Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho.

Julia M Hum, Linda M O'Bryan, Arun K Tatiparthi, Taryn A Cass, Erica L Clinkenbeard, Martin S Cramer, Manoj Bhaskaran, Robert L Johnson, Jonathan M Wilson, Rosamund C Smith and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Celastrol Attenuates FGF23 Expression in Osteoblasts by Inhibiting STAT3 Activation.Endocrine, metabolic & immune disorders drug targets · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Julia M HumDepartment of Medical and Molecular Genetics, Division of Molecular Genetics and Gene Therapy, Indiana University School of Medicine, Indianapolis, Indiana.
Linda M O'BryanBiotechnology Discovery Research, Lilly Research Laboratories.
Arun K TatiparthiLead Optimization Toxicology and Pharmacology, Covance Inc., Greenfield, Indiana.
Taryn A CassDepartment of Medical and Molecular Genetics, Division of Molecular Genetics and Gene Therapy, Indiana University School of Medicine, Indianapolis, Indiana.
Erica L ClinkenbeardDepartment of Medical and Molecular Genetics, Division of Molecular Genetics and Gene Therapy, Indiana University School of Medicine, Indianapolis, Indiana.
Martin S CramerBiotechnology Discovery Research, Lilly Research Laboratories.
Manoj BhaskaranInvestigational Pathology, and.
Robert L JohnsonInvestigational Pathology, and.
Jonathan M WilsonTailored Therapeutics, Eli Lilly and Company, Indianapolis, Indiana; and.
Rosamund C SmithBiotechnology Discovery Research, Lilly Research Laboratories, smith_rosamund_c@lilly.com kenewhit@iupui.edu.
Kenneth E WhiteDepartment of Medical and Molecular Genetics, Division of Molecular Genetics and Gene Therapy, Indiana University School of Medicine, Indianapolis, Indiana; smith_rosamund_c@lilly.com kenewhit@iupui.edu.
Indiana University – Purdue University Indianapolis · USCovance (United States) · USEli Lilly (United States) · USIndiana University School of Medicine

Funding

BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASEST32HL007910 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Roland W. Herzog, Reuben Kapur · 1999 to 2026
$7.6M
FGF-23 REGULATION OF PHOSPHATE HOMEOSTASISR01DK063934 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI WHITE, KENNETH E · 2003 to 2015
$3.8M
Control of FGF23 Bioactivity via Circulating alpha-KlothoR01DK095784 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2013 to 2017
$1.7M
Role of iron and hypoxia sensing in FGF23-dependent metabolic bone diseaseF32AR065389 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI CLINKENBEARD, ERICA L · 2014 to 2016
$183k
NHLBI NIH HHS T32 HL007910NIAMS NIH HHS F32 AR065389NIDDK NIH HHS R01 DK063934NIDDK NIH HHS R01 DK095784
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBone and BonesChronic DiseaseDiabetic NephropathiesDisease Models, AnimalFemaleFibroblast Growth Factor-23GlucuronidaseHyperphosphatemiaKlotho ProteinsMaleMiceMice, KnockoutVascular CalcificationFgf23 protein, mouseFibroblast Growth Factor-23GlucuronidaseKlotho Proteinsalpha-klothobonedb/db-eNOSFGF23hyperphosphatemiaosteocyte

Identifiers

PMID27837149
PMCPMC5373441
OpenAlexW2556220537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.